Suchergebnisse - "KE CHANGWEN"

PubPharm (17)

1

Potent Antibody Response Elicited by a Third Booster Dose of Inactivated COVID-19 Vaccine in Healthy Subjects

enthalten in: Viral immunology | 2023

von Ji, R. | Zhang, J. | Liang, D. | +9

2

SARS-CoV-2 ORF3a sensitizes cells to ferroptosis via Keap1-NRF2 axis

enthalten in: Redox biology | 2023

von Liu, L. | Du, J. | Yang, S. | +12

3

Progress of the COVID-19 : Persistence, Effectiveness, and Immune Escape of the Neutralizing Antibody in Convalescent Serum

enthalten in: Pathogens (Basel, Switzerland) | 2022

von Liang, D. | Zhang, G. | Huang, M. | +14

4

Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants

enthalten in: Virology journal | 2022

von Liao, G. | Lau, H. | Liu, Z. | +32

5

Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants

enthalten in: Virology journal | 2022

von Liao, G. | Lau, H. | Liu, Z. | +32

6

Single-dose rAAV5-based vaccine provides long-term protective immunity against SARS-CoV-2 and its variants

enthalten in: Virology journal | 2022

von Liao, G. | Lau, H. | Liu, Z. | +32

7

Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection

enthalten in: Emerging microbes & infections | 2022

von Liang, H. | Zheng, P. | Wang, Q. | +16

8

Long-term asymptomatic SARS-CoV-2 infection associated with deficiency on multiple immune cells

enthalten in: Biosafety and health | 2022

von He, G. | Chuai, X. | Liang, D. | +6

9

Development of Receptor Binding Domain (RBD)-Conjugated Nanoparticle Vaccines with Broad Neutralization against SARS-CoV-2 Delta and Other Variants

enthalten in: Advanced science (Weinheim, Baden-Wurttemberg, Germany) | 2022

von Chen, R. | Zhang, X. | Yuan, Y. | +26

10

Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China

enthalten in: Innovation (Cambridge (Mass.)) | 2022

von Liu, Q. | Xiong, Q. | Mei, F. | +23